14-day Premium Trial Subscription Sign Up For FreeGet Free

When Should You SELL Your Stocks? Click to watch.

Celsion Corporation Stock Forecast

NASDAQ:CLSN BUY SELL

$2.34 (-5.26%)

Volume: 85.477k

Closed: May 19, 2022

Hollow Logo Score: -7.330

Celsion Corporation Stock Forecast

BUY SELL NASDAQ:CLSN
$2.34 (-5.26%)

Volume: 85.477k

Closed: May 19, 2022

Score Hollow Logo -7.330

Celsion Corporation Stock Forecast NASDAQ:CLSN

Price Target and Analyst Ratings

Historical Ratings

Date Upside / Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
2022-04-13 583.76% HC Wainwright & Co. $16.00 Initiates Coverage On Buy
2020-07-16 - Oppenheimer - Downgrades Outperform Perform

CLSN Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -41.97% during the next 3 months and, with a 90% probability hold a price between $0.91 and $2.64 at the end of this 3-month period.

Data

Date Bottom Mid Top
2022-05-23 $1.51 $3.00 $4.49
2022-05-24 $1.45 $2.95 $4.44
2022-05-25 $1.40 $2.89 $4.39
2022-05-26 $1.34 $2.84 $4.33
2022-05-27 $1.29 $2.78 $4.28
2022-05-31 $1.24 $2.73 $4.22
2022-06-01 $1.18 $2.68 $4.17
2022-06-02 $1.13 $2.62 $4.12
2022-06-03 $1.07 $2.57 $4.06
2022-06-06 $1.02 $2.51 $4.01
2022-06-07 $0.97 $2.46 $3.96
2022-06-08 $0.91 $2.41 $3.90
2022-06-09 $0.86 $2.35 $3.85
2022-06-10 $0.81 $2.30 $3.79
2022-06-13 $0.75 $2.25 $3.74
2022-06-14 $0.70 $2.19 $3.69
2022-06-15 $0.64 $2.14 $3.63
2022-06-16 $0.59 $2.08 $3.58
2022-06-17 $0.54 $2.03 $3.52
2022-06-21 $0.48 $1.98 $3.47
2022-06-22 $0.43 $1.92 $3.42
2022-06-23 $0.37 $1.87 $3.36
2022-06-24 $0.32 $1.81 $3.31
2022-06-27 $0.27 $1.76 $3.25
2022-06-28 $0.21 $1.71 $3.20
2022-06-29 $0.16 $1.65 $3.15
2022-06-30 $0.10 $1.60 $3.09
2022-07-01 $0.0502 $1.54 $3.04
2022-07-05 $-0.0037 $1.49 $2.98
2022-07-06 $-0.0576 $1.44 $2.93

About Celsion Corporation

Celsion Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It has a developme... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!
.

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT